We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of carboplatin sustained-release delivery system in dogs with cancer.
- Authors
Tansey Baldwin, Colleen; Zwahlen, Courtney H.; Kirschner, Steven; Nakamura, Reid K.
- Abstract
The objective of the study was to assess the carboplatin sustained-release ( CSR) as an injectable, biodegradable polymer system designed to uniformly release carboplatin over 30 days at a dose of 350 mg m−2. The study involved seven client-owned dogs with histologically or cytologically confirmed neoplasia that were treated with CSR intramuscularly. Platinum levels were measured at days 0, 7, 14, 21 and 28. Complete blood cell ( CBC) counts, body weight, local toxicity and side effects were also evaluated at the time of platinum measurement at days 0, 7, 14, 21 and 28. CSR released carboplatin steadily over 30 days. Neutropenia was noted as Grade 3 in one dog (14%) and Grade 4 in two dogs (29%) at day 14, and Grade 4 in one dog (14%) at day 21. Thrombocytopenia was noted as Grade 2 in four dogs (57%), Grade 3 in one dog (14%) and Grade 4 in one dog (14%) at day 14; Grade 2 in two dogs (29%) and Grade 3 in one dog (14%) at days 21 and 28. Grade 1 lethargy in one dog (14%) and Grade 1 nausea in dog (14%) occurring within 7 days after administration. No obvious local injection site reactions were noted. CSR administered at 350 mg m−2 intramuscularly resulted in a steady release over 30 days. Myelosuppression (Grade 4) was noted in 86% of patients. CSR released the drug slowly and steadily, however additional studies are needed to assess acceptable dosage requirements.
- Subjects
CANCER in dogs; CARBOPLATIN; POLYMERS; BLOOD cell count; DOG diseases
- Publication
Veterinary Medicine & Science, 2016, Vol 2, Issue 3, p147
- ISSN
2053-1095
- Publication type
Article
- DOI
10.1002/vms3.26